TG Therapeutics, Inc. (NASDAQ: TGTX) shares climbed in Tuesday’s extended trading after the company released its preliminary ...
The company sees 2025 revenue of $616 million compared to the analysts’ consensus estimate of $606.03 million, according to ...
Zacks Investment Research on MSN
TG Therapeutics stock rises 7% on strong Q4 & 2025 preliminary results
TG Therapeutics’ TGTX shares rose nearly 7% in after-hours trading, following the release of preliminary fourth-quarter and ...
TG Therapeutics is winding down its oncology program after removing the FDA-approved cancer med Ukoniq from the market in two indications that were granted accelerated approval in addition to ...
TG Orthodontics Honored as a 2026 Top Dentist by Monmouth Magazine Marlboro Township, United States - January 8, 2026 / ...
A TG Therapeutics multiple sclerosis drug that’s new to the U.S. market will be commercialized in Europe and other regions under a partnership that pays the biotech $140 million up front. According to ...
Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback